Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fesoterodine
Drug ID BADD_D00891
Description Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved
ATC Code G04BD11
DrugBank ID DB06702
KEGG ID D07226
MeSH ID C526675
PubChem ID 6918558
TTD Drug ID D00BLL
NDC Product Code 47621-025; 50370-0047
UNII 621G617227
Synonyms fesoterodine | toviaz | fesoterodine fumarate
Chemical Information
Molecular Formula C26H37NO3
CAS Registry Number 286930-02-7
SMILES CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonic bladder20.03.03.003; 17.10.01.0030.004217%Not Available
Hypokalaemia14.05.03.0020.000496%
Hyponatraemia14.05.04.0020.000992%
Hypotension24.06.03.002--
Ileus07.13.01.0010.002481%
Impaired gastric emptying07.02.02.0040.000496%
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.001340%Not Available
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.000744%Not Available
Intestinal obstruction07.13.01.0020.002233%Not Available
Irritable bowel syndrome07.02.04.003; 19.24.01.003--Not Available
Laryngeal pain22.12.03.010--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000992%Not Available
Lymphoedema24.09.01.001; 01.09.01.0060.001687%
Malaise08.01.01.0030.014190%
Memory impairment19.20.01.003; 17.03.02.0030.005805%
Mental impairment19.21.02.003; 17.03.03.0020.000496%Not Available
Micturition disorder20.02.02.005--Not Available
Micturition urgency20.02.02.0060.004118%
Middle insomnia19.02.01.003; 17.15.03.0030.001092%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.001985%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.001240%
Nasal dryness22.04.03.0020.000496%Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.0010.000992%Not Available
Nervous system disorder17.02.10.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages